1 week ago
Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results
Spyre Therapeutics (SYRE) stock climbs 2% after Guggenheim names it top biotech pick. SPY003 Phase II ulcerative colitis data shows promise. Analysis inside.
The post Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 9 hours ago
Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers P...
- 10 hours ago
PayPal Holdings, Inc. (PYPL) Stock: Muse Partnership Opens New AI Commerce Route
- 10 hours ago
Amazon.com, Inc. (AMZN) Stock: Amazon Blocks Meta’s Muse Shopping Agent
- 11 hours ago
SpaceX (SPCX) Stock: Advances as Merger Speculation Drives Attention
- 11 hours ago
NVIDIA (NVDA) Stock: Gains as Apple Challenges Cloud AI With New Macs